Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer. by Slebos, R. J. et al.
Br. J. Cancer (1989), 59, 76-80 © The Macmillan Press Ltd., 1989~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Cellular protoonocogenes are infrequently amplified in untreated non-
small cell lung cancer
R.J.C. Slebos', S.G. Evers', S.S. Wagenaar2 and S. Rodenhuis'
'Departments of Experimental Therapy and Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX
Amsterdam, The Netherlands and 2Department of Pathology, St Antonius Hospital, Nieuwegein, The Netherlands.
Summary To examine a potential contribution of protooncogene abnormalities other than point-mutational
activation of the K-ras protooncogene in the classification of non-small cell lung cancer, amplification of
cellular protooncogenes was studied in 47 lung tumour specimens obtained at thoracotomy and in four lung
tumour cell lines. The primary tumours included 21 adenocarcinomas, nine large-cell carcinomas, 13
epidermoid carcinomas, one carcinoid and three metastases of primaries outside the lung. The copy numbers
per haploid genome of 11 protooncogenes in every tumour sample were determined: H-ras, K-ras, N-ras, c-
myc, N-myc, L-myc, erbB, mos, myb, neu (erbB-2) and ral amplifications. The c-myc gene was amplified 5-7-
fold in two adenocarcinomas, the H-ras gene 3-5-fold in one adenocarcinoma, while the K-ras and the neu
gene were amplified in lung metastases from a colorectal and a breast cancer primary respectively. None of
the tumours with an amplified protooncogene simultaneously harboured a mutationally activated K-ras gene.
We conclude that amplification of the investigated protooncogenes is a rare event in non-small cell lung
cancer. In view of the two c-myc amplifications detected, a systematic study of c-myc expression levels in non-
small cell lung cancers appears worthwhile.
Lung cancer is usually divided in four major types: small cell
carcinoma (representing 25%), epidermoid carcinoma (30%),
adenocarcinoma (25%) and large-cell carcinoma (15%), with
uncommon or mixed types making up the remaining 5%
(Sobin, 1982). The distinction between small cell lung carci-
noma (SCLC) and non-small cell lung carcinoma (NSCLC)
is clinically important because SCLC is treated mostly with
chemotherapy while the treatment of choice in NSCLC is
surgery. NSCLC, in turn, comprises a heterogeneous group
of tumours, the classification of which might possibly be
improved by determining the activation of protooncogenes in
the tumours. It is hoped that elucidation of the genetic
mechanisms in lung cancer will eventually result in the
design of improved treatment strategies.
The primary candidates in the search for the pathogenic
mechanisms in cancer are the known cellular proto-
oncogenes, which have been shown to be important in the
transformation of cells in several model systems (for review
see Varmus, 1984). Activation of these oncogenes can result
from several mechanisms, including gene amplification,
allelic deletion, gene rearrangement or certain (point-) muta-
tion(s) in the protooncogene sequences (for reviews see
Nishimura & Sekiya, 1987; Alitalo & Schwab, 1986). In
some cases protooncogene activation correlates well with
tumour type or with biological behaviour of the tumour
(Yokota et al., 1986b; Seeger et al., 1986; Slamon et al.,
1987). Of the known protooncogenes, only a few have been
found to be consistently altered in human lung carcinoma
(for review see Rodenhuis, 1988). Amplification of the
cellular protooncogenes of the myc family has been observed
in primary SCLC tumours in several studies (Nau et al.,
1985; Wong et al., 1986; Brooks et al., 1987), and has in
some cases been correlated with clinical behaviour (Johnson
et al., 1987; Funa et al., 1987). In NSCLC, several proto-
oncogene aberrations have been described, including amplifi-
cation of c-myc (Yokota et al., 1986b; Cline & Battifora,
1987), N-myc (Saksela et al., 1986), ras (Pulciani et al., 1985;
Vousden et al., 1986), erbB (Yokota et al., 1986a; Cline &
Battifora, 1987; Berger et al., 1987), and neu (Cline &
Battifora, 1987) genes. Other genetic abnormalities, such as
loss of H-ras and myb alleles (Cline & Battifora, 1987) or
chromosomal deletion of an unknown gene on the short arm
of chromosome 3 (Naylor et al., 1987; Kok et al., 1987) have
also been reported.
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We have previously shown that the K-ras protooncogene
is activated by point-mutation in about a third of all
adenocarcinomas of the lung (Rodenhuis et al., 1987, 1988).
In addition to screening our NSCLC DNAs for this type of
oncogene activation, we subjected the samples to Southern
blotting analysis to detect possible oncogene amplification. A
total of 11 genes we?e4 examined, concentrating on those
which have been described amplified in human primary
(lung) tumours. Any consistent protooncogene amplifications
might thus be correlated with the clinical data available on
the patient donating the tumour.
Materials and methods
Lung carcinoma specimens were obtained at surgical resec-
tion in The Netherlands Cancer Institute, The Antonius
Hospital in Nieuwegein or at one of the regional hospitals
collaborating in the study. After transportation to the path-
ology department, a representative part of the tumour was
snap-frozen and stored at -70 °C until analysis. Before
isolation of cellular DNA, cryostat sections were obtained
and the percentage of tumour cells in the specimen was
estimated. Non-neoplastic regions were carefully removed so
that the final tumour specimens contained 50% or more
neoplastic cells.
Of 48 patients, 21 had adenocarcinomas, 13 epidermoid
carcinomas, and 9 had large-cell carcinomas according to the
World Health Organization classification (Sobin, 1982). The
four remaining tumours were a carcinoid and three lung
metastases, three from colorectal and one from a breast
primary (Table I). Classification of the tumour specimens
was done independently by two diagnostic histopathologists
(S.S.W. and W.J. Mooi). Clinical parameters such as tumour
size, tumour spread, smoking habits, interval to recurrence,
etc., were obtained by reviewing the hospital charts. The cell
lines A549 and NCI-H23 have been described previously
(Lieber et al., 1976; Carney et al., 1985). The GLC-Al and
GLC-A2 cell lines are human lung adenocarcinoma cell lines
and were a gift from Dr L.F.H.M. de Leij from the
University of Groningen, The Netherlands.
DNA was isolated using standard techniques and used for
dot-blotting and for Southern blotting as described pre-
viously (Rodenhuis et al., 1987). For Southern blotting the
samples were digested with the indicated restriction enzymes
(obtained from Boehringer Mannheim, Mannheim, Federal
Republic of Germany), separated on 0.8% agarose gels and
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blotted onto Hybond membranes (Amersham International,
Amersham, UK) using procedures as indicated by the manu-
facturer. Protooncogene probes were nick-translated and
hybridised to the filters using standard techniques (Janssen et
al., 1985). The following molecular probes were used: H-ras
'pEJ' (Goldfarb et al., 1982), K-ras 'pLC3' (Shimizu et al.,
1983), N-ras 'clone B' (Hall et al., 1983), c-myc 'pMC-
413RC' (Dalla-Favera et al., 1982b), N-myc 'pNB-l'
(Schwab et al., 1983), L-myc 'pLmyclO' (Nau et al., 1985),
erbB 'fragment III' (Ullrich et al., 1984), mos 'pHBl' (Wat-
son et al., 1982), myb 'pHM2.8' (Leprince et al., 1983), and
neu 0.4kb BamHI cDNA fragment (Bargmann et al., 1986).
After hybridisation the blots were washed at a final strin-
gency of 0.1 x SSC (SSC is 0.15mol sodium chloride and
0.015 mol trisodium citrate per litre) at 65°C. Control
hybridisations were done with actin encoding sequences from
the pACT-1 plasmid (Dodemont et al., 1982), with a final
wash done in 2xSSC, and 0.5% SDS at 55°C. Autoradio-
graphy was performed with Kodak XAR-5 of XS-1 films at
-70°C using an intensifying screen. Amplifications were
quantified using dot-blot dilution series of the DNAs of
tumours containing protooncogene amplifications.
Results
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Figure 1 Southern blot hybridisations of EcoRI digested
NSCLC DNAs with probes for H-ras, N-ras, ral, myb and
K-ras. Lanes 1 and 3, adenocarcinomas; lane 2, epidermoid
carcinoma; lane 4, large-cell carcinoma. In these four DNAs
none of the hybridisations revealed amplifications of the indi-
cated genes.
A total of 52 DNAs from human non-small cell lung
carcinomas were studied. The histology data of the tumours
from which the DNA was isolated are presented in Table I.
Each DNA sample was analysed by Southern blotting after
digestion with the restriction enzymes HindlIl or EcoRI.
Initially, using the dot-blot technique, we screened all
tumour DNAs for amplifications of the cellular proto-
oncogenes erbB, c-myc and neu. Using this technique we
detected a 10-15-fold amplification of the neu protooncogene
in a solitary metastasis of a breast carcinoma but not in any
of the primary lung carcinomas (results not shown).
Subsequently all tumour DNAs were digested with the
restriction enzyme EcoRI, blotted onto nylon membranes
and hybridised with probes for the three ras, the ral and myb
genes. In Figure 1 an example of such a hybridisation is
shown. After separate hybridisations of these Southern blots,
no abnormal copy numbers of the N-ras, ral or myb gencs
could be detected. The H-ras gene hybridisation is described
below. Hybridisation with the K-ras probe revealed as 15-
20-fold amplification in a solitary lung metastasis of colorec-
tal origin which we described previously (Rodenhuis et al.,
1987), but no K-ras gene amplifications in the other tumour
specimens.
All tumour DNAs were analysed on Southern blots after
digestion with HindIlI. These blots were hybridised with the
probes for the three myc, the erbB, mos and H-ras genes. As
shown in Figure 2, the H-ras gene was found amplified 3-5-
fold in a single adenocarcinoma (lane 1) but not in any other
of the investigated NSCLCs. In addition, a 2-3-fold amplifi-
cation of the H-ras gene was detected in the GLC-A1 cell
line (results not shown). In Figures 2 and 3 examples of
hybridisations with the mos probe are shown, which did not
reveal a single amplification in any of the DNAs. In lane 3
of Figure 2 an amplification of the c-myc gene in an
adenocarcinoma is presented.
Table I Histological classification of the
investigated tumours
Cancer No.
Adenocarcinoma 21
Epidermoid carcinoma 13
Large-cell carcinoma 9
Carcinoid 1
Solitary metastases
Breast 1
Colorectal 3
Adenocarcinoma cell line 4
Total 52
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Figure 2 Southern blot hybridisations of HindIlI digested
NSCLC DNAs with probes for c-myc, H-ras and c-mos, and
actin control. Lanes 1, 2 and 3 are from adenocarcinomas. In
lane 1 an amplification of the H-ras gene is present, while the
sample in lane 3 shows an amplification of the c-myc gene.
In Figure 3 the Southern blot hybridisations are shown of
six representative, Hindlll digested tumour DNA samples
hybridised with probes for c-myc, L-myc and N-myc as well
as for erbB and mos. In lane 4 the probe for c-myc detects a
5-7-fold amplification of this gene. This stronger signal is
not seen with either the N- or L-myc protooncogene probes.
Amplification of a c-myc gene could be detected in two of 48
tumours, both of which were adenocarcinomas (Table II).
The N- and L-myc genes were not amplified in any of the
DNAs we investigated, and neither was the erbB gene.
Discussion
Activation of protooncogenes by amplification is a well
studied mechanism that has been reported for several
primary human tumours. These include c-myc in SCLC and
NSCLC and in other cancers, N-myc in neuroblastoma,
retinoblastoma and chronic myeloid leukaemia, c-myb in
acute myeloid leukaemia, H-ras and K-ras in bladder carci-
noma, and neu in adenocarcinomas of the stomach and
breast. Amplifications have also been found in many cell
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Figure 3 Southern blot hybridisations of HinidlIl digested
NSCLC DNAs with probes for c-iivc, L-mvc, N-/niv, crbB and
mos, and with the actin control. Lanes I and 3, epidermoid
carcinomas; lanes 2, 4 and 5, large-cell carcinomas; lane 6, lung
metastasis of colorectal primary. The samples in lanes 1, 2, 3, 5
and 6 show normal copy numbers of the indicated genes. In lane
4 an amplification of the c-myc gene is shown.
lines derived from human tumours (for reviews see
Nishimura & Sekiya, 1987; Alitalo & Schwab, 1986). These
data should be interpreted with caution, however, since
somatic amplification of genes has been implicated in several
adaptive responses of cells to environmental stresses. Selec-
tion for drug resistant subpopulations of cells may give rise
to double-minute chromosomes (DMs) or to homogeneously
staining regions (HSRs), which represent large regions of
amplified DNA. Serial passage of cells in culture may also
select for cells with gene amplifications (Alitalo & Schwab,
1986). Thus it is conceivable that some amplifications of
protooncogenes in human tumours may only reflect the
presence of a specific selection pressure, such as chemo-
therapy, rather than play a role in the pathogenesis of the
tumour. For this reason we concentrated on lung tumours
from patients with limited disease, who had not received
chemotherapy before surgery.
In 48 primary NSCLC and in four NSCLC derived cell
lines no amplifications of the cellular protooncogenes myb or
mos were detected. Since the c-mos gene is localised on
chromosome 8 in the same region as c-myc, the detected
increased copy numbers of c-myc are likely to result from
gene amplification rather than from chromosome
duplication.
Although several reports indicate that the c-erbB proto-
oncogene, encoding the epidermal growth factor receptor
(EGFR), has a role in the carcinogenesis of human lung
cancer, we did not find any abnormal copy numbers of this
gene. Recently published data on this subject indicate that
enhanced levels of the EGFR frequently occur in epidermoid
lung carcinomas (Berger et al., 1987) and less commonly in
other NSCLC types (Veale et al., 1987). High expression of
erbB does not necessarily require amplification of the gene,
as has been shown in a study including 25 NSCLC (Lee et
al., 1987). Furthermore, high expression of the EGFR has
been observed in several different tumour types and cell lines
without amplification of the gene (Alitalo & Schwab, 1986).
Although the erbB gene has been found amplified in some
NSCLCs (Cline & Battifora, 1987), overexpression of the
EGF receptor without amplification appears to occur much
more frequently. These data combined with our findings
indicate that activation by amplification of the erbB gene
may represent only a minority of the activational mecha-
nisms of increased EGFR expression.
Similar to the apparent involvement of the erbB gene in
the carcinogenesis of epidermoid tumours, the neu
protooncogene may have a role in the pathogenesis of
adenocarcinomas. This gene has been reported to be ampli-
fied in five of 63 glandular tumours, but not in the three
adenocarcinomas of the lung which were also investigated
(Yokota et al., 1986a). In about 20% of breast carcinomas
the neu gene is found amplified (Van De Vijver et al., 1987),
a phenomenon that appears to have clinical implications
(Slamon et al., 1987). This report shows that in 21 lung
adenocarcinomas not a single amplified neu gene was
present. We thus conclude that this gene is not frequently
amplified in NSCLC. The only case of a neu amplification
we did detect was in a solitary lung metastasis of a breast
carcinoma. A similar case of neu amplification in a lung
metastasis from a breast primary has been described for a
case in which the primary tumour had normal copy numbers
of the gene (Yokota et al., 1986a). Thus, amplification of the
neu gene might in some cases aid in distinguishing different
types of adenocarcinoma.
Members of the ras family of protooncogenes are
expressed in many normal and tumour cells (for review see
Bos, 1988). These genes have been described as being altered
in human lung tumours by amplification (Pulciani et al.,
1985; Vousden et al., 1986) as well as by point mutation
(Rodenhuis et al., 1987), both types of activation also being
frequently observed in cell lines (Nishimura & Sekiya, 1987).
In our series of NSCLC specimens we have described the
frequent (about 30%) mutational activation of the K-ras
gene in lung adenocarcinomas, but not in other types of
NSCLC (Rodenhuis et al., 1988). The K-ras and N-ras
protooncogenes were not amplified in any of the primary
lung carcinomas. This result is in agreement with other
studies (Heighway & Hasleton, 1986; Cline & Battifora,
1987). The only ras amplification we found in this study was
of the H-ras gene in a single adenocarcinoma, which was K-
ras mutation negative. This is the first time an H-ras
protooncogene amplification is detected in a fresh tumour
specimen of a NSCLC. In general, however, amplifications
of the ras genes are rare in NSCLC.
Ras gene abnormalities in lung metastases of colorectal
origin seem to occur more frequently: of four studied
samples one had a K-ras amplification, while two others
harboured ras gene mutations, one in N-ras cordon 61 and
one in K-ras codon 12 (Rodenhuis et al., 1988). These
mutations are known to occur with some frequency in colon
cancers (Bos et al., 1987). Thus, three of four colorectal
metastases to the lung (including one we did not test for ras
amplification) contain an activated ras protooncogene. It is
Table II Summary of tumours with oncogene amplifications
Patient TNM Oncogene Level of
no. Age Histology category amplified amplification
18 68 Metastasis of colorectal cancer - K-ras 15-20 x
19 53 Metastasis of breast cancer - c-neu 10-15 x
42 57 Large-cell TINOMO c-myc 5- 7 x
102 65 Adenocarcinoma TINIMO H-ras 3- 5 x
107 71 Adenocarcinoma T2NOMO c-myc 5- 7 x
GLC-Al - Adenocarcinoma cell line - H-ras 2- 3 xCELLULAR PROTOONCOGENES 79
tempting to speculate that ras activations of any type may be
associated with the ability of colorectal cancer cells to
metastasise to the lungs. In several model systems a correla-
tion between ras expression and metastasis formation has
been described, including that of H-ras transfected NIH-3T3
fibroblasts (Egan et al., 1987), and a system of mouse T-
lymphoma cells (Collard et al., 1987).
The myc family of protooncogenes has frequently been
found to be altered in lung cancer, although most of the
data focus on SCLC and SCLC-derived cell lines. The latter
tend to have amplified myc genes (Johnson et al., 1987;
Kiefer et al., 1987), which is reflected by overexpression at
the mRNA level (Ibson et al., 1987). Amplifications of the
cellular myc genes in primary SCLC have also been de-
scribed, but these occur with much lower frequency than in
SCLC cell lines (Saksela et al., 1986; Wong et al., 1986). For
NSCLC only a few studies report myc gene amplifications in
primary tumours. The c-myc gene was observed to be
amplified in one of two bronchioloalveolar carcinomas
(Yokota et al., 1986b), and in three of 26 NSCLC, all
adenocarcinomas (Cline & Battifora, 1987). Our findings
confirm that the c-myc protooncogene is amplified in a
minority of NSCLCs, in our study two of 48 samples, one
large-cell carcinoma and one adenocarcinoma. It thus
appears that the c-myc amplifications, though infrequent in
NSCLCs, mainly occur in adenocarcinomas. In SCLC, c-myc
amplification has been reported to correlate with a poor
prognosis (Johnson et al., 1987). Whether or not this is also
the case in NSCLC cannot be determined at present.
Two other members of the myc gene family, N-myc and L-
myc (Schwab et al., 1983; Nau et al., 1985), commonly
amplified in SCLC cell lines, have occasionally been de-
scribed to be amplified in uncultured lung tumours (Minna
et al., 1986; Saksela et al., 1986). In our series no N- or L-
myc amplifications could be detected. An important role for
amplification of these genes in NSCLC is thus unlikely.
Future investigations will have to elucidate the occurrence of
other myc gene activations such as overexpression or translo-
cation in NSCLC.
Since we previously screened in NSCLC DNAs for muta-
tional activation of the cellular ras genes (Rodenhuis et al.,
1987, 1988), the simultaneous presence of an amplified
protooncogene with a mutated ras gene could be examined.
At least for one lung carcinoma xenograft maintained in
nude mice it has been described that an amplified and
mutationally activated K-ras gene can occur simultaneously
with an amplified c-myc gene (Taya et al., 1984). Despite the
relatively high frequency of K-ras codon 12 mutations in our
series, we did not detect alterations of more than a single
protooncogene. Thus it seems probable that one or more yet
unidentified protooncogenes can complement for K-ras
mutations and/or protooncogene amplifications in the patho-
genesis of human lung cancer.
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